Omnicom and Interpublic Clear Australia Antitrust Review
Get Alerts OMC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4%
Revenue Growth %: +60.7%
Join SI Premium – FREE
The ACCC approval brings the total number of antitrust approvals to 14 out of the 18 required for closing. The companies remain firmly on track to complete the transaction in the second half of 2025.
The proposed merger of Omnicom and Interpublic will reimagine the marketing industry, ushering in a bold new era of growth for its people, delivering superior outcomes for clients, and generating significant long-term value for shareholders.
About Omnicom
Omnicom (NYSE: OMC) is a leading provider of data-inspired, creative marketing and sales solutions. Omnicom's iconic agency brands are home to the industry's most innovative communications specialists who are focused on driving intelligent business outcomes for their clients. The company offers a wide range of services in advertising, strategic media planning and buying, precision marketing, retail and digital commerce, branding, experiential, public relations, healthcare marketing and other specialty marketing services to over 5,000 clients in more than 70 countries. For more information, visit www.omnicomgroup.com.
About IPG
Interpublic (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively driven provider of marketing solutions. Home to some of the world's best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Initiative, IPG Health, IPG Mediabrands,
View original content:https://www.prnewswire.com/news-releases/omnicom-and-interpublic-clear-australia-antitrust-review-302508262.html
SOURCE Omnicom Group Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- V&V Supremo® Earns Top Honors at 2026 American Cheese Society Judging & Competition
- HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
- AI Coalition for Social Impact, Convened by Blackbaud, Officially Opens the Free AI for Social Impact Certification Program
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share